{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:21:52Z","timestamp":1794255712067,"version":"4.9.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ymgme.2026.110281","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:51:00Z","timestamp":1791215460000},"page":"110281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and management of patients with mucopolysaccharidosis II in the United States enrolled in the Hunter Outcome Survey"],"prefix":"10.1016","volume":"149","author":[{"given":"Barbara K.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Ficicioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Eisengart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.110281_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.012","article-title":"Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States","volume":"25","author":"Ream","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110281_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijns6030073","article-title":"Newborn screening for mucopolysaccharidosis type II in Illinois: an update","volume":"6","author":"Burton","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2026.110281_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/ijns6040079","article-title":"Validation and implementation of a highly sensitive and efficient newborn screening assay for mucopolysaccharidosis type II","volume":"6","author":"Bilyeu","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2026.110281_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107557","article-title":"Newborn screening for mucopolysaccharidosis type II: lessons learned","volume":"140","author":"Burton","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110281_bb0025","unstructured":"Pennsylvania; State Newborn Screening Panel, Health Resources and Services Administration. 2026."},{"key":"10.1016\/j.ymgme.2026.110281_bb0030","unstructured":"West Virginia; State Newborn Screening Panel, Health Resources and Services Administration. 2026."},{"key":"10.1016\/j.ymgme.2026.110281_bb0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpeds.2019.09.036","article-title":"Newborn screening for mucopolysaccharidoses: results of a pilot study with 100 000 dried blood spots","volume":"216","author":"Scott","year":"2020","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2026.110281_bb0040","author":"North Carolina Department of Health and Human Services"},{"key":"10.1016\/j.ymgme.2026.110281_bb0045","article-title":"ScreenPlus: a comprehensive, multi-disorder newborn screening program","volume":"38","author":"Kelly","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110281_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110281_bb0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome\u2014an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2026.110281_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008185.pub4","article-title":"Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)","author":"da Silva","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymgme.2026.110281_bb0065","unstructured":"E.F. Neufeld, J. Muenzer, The mucopolysaccharidoses, in: C.R. Scriver, A.L. Beaudet, S. W.S., D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York."},{"key":"10.1016\/j.ymgme.2026.110281_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations \u2013 neurological signs and symptoms","volume":"122S","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110281_bb0075","article-title":"The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome","volume":"22","author":"Eisengart","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110281_bb0080","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2026.110281_bb0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","article-title":"The natural history of neurocognition in MPS disorders: a review","volume":"133","author":"Shapiro","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110281_bb0090","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II\u2014a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110281_bb0095","first-page":"32","article-title":"A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II","volume":"7","author":"Shapiro","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110281_bb0100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","article-title":"Health-related quality of life in patients with MPS II","volume":"24","author":"Needham","year":"2015","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ymgme.2026.110281_bb0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.36469\/jheor.2022.33801","article-title":"Clinical characteristics and healthcare resource utilization for patients with mucopolysaccharidosis II (MPS II) in the United States: a retrospective chart review","volume":"9","author":"Ayodele","year":"2022","journal-title":"J. Health Econ. Outcomes Res."},{"key":"10.1016\/j.ymgme.2026.110281_bb0110","author":"ELAPRASE\u00ae (idursulfase) injection, for intravenous use"},{"key":"10.1016\/j.ymgme.2026.110281_bb0115","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2026.110281_bb0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110281_bb0125","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2026.110281_bb0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110281_bb0135","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110281_bb0140","article-title":"Timing is everything: clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair","volume":"30","author":"Grant","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2026.110281_bb0145","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110281_bb0150","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up","volume":"101","author":"Tylki-Szymanska","year":"2012","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2026.110281_bb0155","first-page":"9","article-title":"Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: a case report","volume":"62","author":"Tomita","year":"2021","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110281_bb0160","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter outcome survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110281_bb0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110281_bb0170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/pbc.24361","article-title":"Race matters: perceptions of race and racism in a sickle cell center","volume":"60","author":"Nelson","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ymgme.2026.110281_bb0175","article-title":"Disease-specific health disparities: a targeted review focusing on race and ethnicity","volume":"10","author":"Cullen","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.ymgme.2026.110281_bb0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/gim.2013.162","article-title":"A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4\u20137.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy","volume":"16","author":"Giugliani","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110281_bb0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110281_bb0190","first-page":"99","article-title":"Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age","volume":"14","author":"Lampe","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110281_bb0195","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13023-020-01598-z","article-title":"Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985\u20132019)","volume":"15","author":"Lin","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110281_bb0200","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cca.2021.10.020","article-title":"Identification and structure characterization of novel IDS variants causing mucopolysaccharidosis type II: a retrospective analysis of 30 Chinese children","volume":"523","author":"Zhao","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2026.110281_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2026.110281_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107652","article-title":"Cognitive and adaptive behaviors associated with disease severity and genotype in patients with mucopolysaccharidosis II","volume":"140","author":"Yee","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110281_bb0215","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/GIM.0b013e3181f6e74d","article-title":"Outcome survey, importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter outcome survey","volume":"12","author":"Mendelsohn","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2026.110281_bb0220","series-title":"Afraid of the Doctor: Every Parent's Guide to Preventing and Managing Medical Trauma","author":"Marsac","year":"2021"},{"key":"10.1016\/j.ymgme.2026.110281_bb0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13023-018-0827-1","article-title":"Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS)","volume":"13","author":"Lin","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110281_bb0230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2020.08.007","article-title":"Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints","volume":"131","author":"van der Lee","year":"2020","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226005640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:31:52Z","timestamp":1794252712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226005640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1096719226005640"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110281","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and management of patients with mucopolysaccharidosis II in the United States enrolled in the Hunter Outcome Survey","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Takeda Pharmaceuticals Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110281"}}